EUVIMEDEUVIMED entdecken
Open Access

Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?

Mariëtte E G Kranendonk iD, Raoull Hoogendijk, Julie A S Lammers, Jasper van der Lugt, Nelleke Tolboom, Esther van Mastrigt, Ella de Boed, Thijs J M van den Broek, Lennart A Kester, Dannis G van Vuurden, Bastiaan B J Tops iD, Eelco W Hoving und 2 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Mariëtte E G Kranendonk und 13 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: B7 Antigens, Central Nervous System Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: internal funding sources of the Princess Máxima Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pediatric high-grade central nervous system (pHG-CNS) tumors are the leading cause of childhood cancer-related deaths, partly due to poor response to standard treatments. B7-H3 is reportedly expressed in pHG-CNS tumors, making antigen-targeting therapies, including anti-B7-H3 chimeric antigen receptor T-cell (CAR-T) therapy, promising. However, given substantial inter-tumoral protein expression diversity in CNS tumors, it’s unclear which patients might benefit from these treatments. Therefore, we studied B7-H3 expression in a large set of pHG-CNS tumors.

Methods

We retrospectively analyzed 136 pHG-CNS tumors (embryonal tumors (n = 44), high-grade neuroepithelial tumors (n = 4), ependymomas (n = 30),high-grade gliomas (HGGs, n = 58)) from the Princess Máxima Center for Pediatric Oncology. CD276 mRNA (encoding B7-H3) and immunohistochemical (IHC) protein expression of B7-H3 was measured and correlated to clinical-molecular data.

Results

Large variability of B7-H3 mRNA and protein expression was observed both between and within tumor types. Many tumors expressed B7-H3, but 30% of diffuse midline glioma H3K27-altered and ependymomas posterior fossa type A showed no or minimal expression. This variability was unrelated to patient age, tumor location, epigenetic subclass, or molecular tumor driver. B7-H3 negative cases were high in tumor cells, ruling out low tumor cell percentage as an explanation for negative staining.

Conclusions

Our study of B7-H3-expression in the largest pHG-CNS tumor set to date revealed significant interpatient variability and numerous negative cases. Our results urge for tumor tissue acquisition at enrollment in B7-H3 targeting therapeutic trials (including CAR-T cells) in order to thoroughly assess the value of IHC B7-H3 expression as biomarker and, ultimately, to allow for more tailored therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7 AntigensCentral Nervous System NeoplasmsBiomarkers, TumorHumansChildRetrospective StudiesFemaleChild, PreschoolMaleImmunohistochemistryAdolescentFollow-Up StudiesPrognosisInfantNeoplasm GradingClinical Trials as Topic

Stichwörter der Autor:innen

B7-H3antigen-targeting therapydiffuse midline gliomapediatric CNS tumor

Substanzen

B7 AntigensCD276 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department of Neurology, Brain Tumor Center, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
  • Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht, The Netherlands.
  • Department of Pathology, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.

ORCID-Profile: Mariëtte E G Kranendonk, Bastiaan B J Tops

Förderung

  • internal funding sources of the Princess Máxima Center

Zitieren

APA

Kranendonk, M. E. G., Hoogendijk, R., Lammers, J. A. S., van der Lugt, J., Tolboom, N., van Mastrigt, E., de Boed, E., van den Broek, T. J. M., Kester, L. A., van Vuurden, D. G., Tops, B. B. J., Hoving, E. W., Wesseling, P., & Plasschaert, S. L. A. (2025). Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf095

Vancouver

Kranendonk MEG, Hoogendijk R, Lammers JAS, van der Lugt J, Tolboom N, van Mastrigt E, et al. Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf095

BibTeX
@article{Kranendonk2025,
  author = {Kranendonk, Mariëtte E G and Hoogendijk, Raoull and Lammers, Julie A S and van der Lugt, Jasper and Tolboom, Nelleke and van Mastrigt, Esther and de Boed, Ella and van den Broek, Thijs J M and Kester, Lennart A and van Vuurden, Dannis G and Tops, Bastiaan B J and Hoving, Eelco W and Wesseling, Pieter and Plasschaert, Sabine L A},
  title = {Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf095}
}
Kostenlos starten →